In vitro optimization of dual-drug lipid carriers improves anticancer efficacy for colon cancer, suggesting a new management strategy.
OBJECTIVE: Lipid-based nanocarriers are versatile nanocarriers that facilitate the loading of both hydrophilic and hydrophobic therapeutic agents. The simultaneous delivery of capecitabine (CAP) and celecoxib (CEL) is anticipated to enhance anticancer efficacy against colon cancer. METHODS: drug release investigations revealed a controlled release profile for both drugs under both acidic and physiological conditions. The hemolysis assay showed hemolysis rate of less than 2%, thereby confirming superior blood compatibility. Stability data indicated that LIPs remained stable for one-month. The developed CAP-CEL-LIPs showed significant cytotoxic potential with enhanced cellular uptake and apoptotic activity against colon cancer cells. CONCLUSION: The engineered CAP-CEL-LIPs could be a promising platform for managing colon cancer.
No takes yet. Share an insight, caveat, or question.
Shewale et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: